Latest posts tagged with #PCSM on Bluesky
PSA50 outcomes with lutetium Lu-177 vipivotide tetraxetan did not differ by race in patients with mCRPC, according to data from retrospective cohort study presented during @ascocancer.bsky.social #GU26 #oncology #pcsm #prostatecancer
Read more here: www.onclive.com/view/racial-...
Thank you to Maha H. Hussain, MD, FACP, FASCO, of @nufeinbergmss.bsky.social for presenting on treatment intensification in mHSPC! Stay tuned to onclive.com for all of our coverage of the 19th Annual NY GU Cancers Congress! #oncology #pcsm #ProstateCancer
📊New data suggest PSA response and PSMA-PET tumor volume don’t always align in patients with biochemically recurrent prostate cancer treated with enzalutamide—raising questions about how imaging should guide treatment decisions. #oncology #GU26 #pcsm
Read more here: www.onclive.com/view/psa-res...
Dr. Scott Tyldesley of UBC reports on 15-year ASCENDE-RT data: Brachytherapy boost halves PC-specific mortality (8.6% vs 16.4%, P=.007) but shows no OS benefit.
Read more here: ➡️ https://bit.ly/3OGoIaH
#pcsm #prostatecancer #ASCOGU26 #GU26
Alicia Morgans, MD, MPH, of @danafarber.bsky.social discusses data from a real-world analysis of androgen pathway receptor triplet regimens in mHSPC that were presented during the 2026 Genitourinary Cancers Symposium. #GU26 #prostatecancer #pcsm
The European indication for niraparib and abiraterone acetate has expanded, with the EC approving the dual action tablets in combination with prednisone/prednisolone and ADT for BRCA1/2-mutated mHSPC #pcsm #oncology www.onclive.com/view/nirapar...
During our #GrandRounds, Dr. Daniel Petrylak was hailed as the ‘Father of Chemotherapy’ for #prostatecancer and shared his excitement for the future: "RIPTACs and bispecifics are incredibly promising, especially when combined with advancements in molecular sequencing." #pcsm
➡️ bit.ly/4rSHOsM
📹Watch: Vincent Picozzi, MD, discusses how data from the phase 3 PANOVA-3 trial are foundational for the evaluation of Optune Pax with other immunotherapies in pancreatic cancer. #oncology #medtwitter #pcsm
👉Watch the full video here: www.onclive.com/view/dr-pico...
🧬 Experts unpack practice-shaping data in RCC, urothelial, & prostate cancer from the 2026 Genitourinary Cancers Symposium — including updates on LITESPARK-022, KEYNOTE-B15, SunRISE-2 & PEACE-3 📊
#GU26 #oncology #medtwitter #kcsm #pcsm
Check it out 👉 www.onclive.com/view/experts...
Nurse-led ERAS protocols for LRP significantly improve recovery. Data show reduced incontinence (32.5% vs 56.5%, P<.001) and shorter hospital stays (5.2 vs 6.1 days). 🩺
From @frontiersin.bsky.social. Read the review: https://bit.ly/4aOgfuR
#MedEd #ProstateCancer #Nursing #pcsm
Thanks to David R. Wise, MD, PhD, of @nyulangone.bsky.social for dropping by for an interview to discuss findings from a phase 1b study of pasritamig plus docetaxel in metastatic castration-resistant prostate cancer. Check out hubs.li/Q045565l0 for all of our coverage of #GU26 #oncology #pcsm
Thank you to Ravi Madan, MD, for stopping by for an interview to discuss a study of enzalutamide monotherapy in biochemically recurrent prostate cancer! Stay tuned to onclive.com for highlights from the interview @ascocancer.bsky.social #GU26 #oncology #pcsm
Cabazitaxel Plus ADT/Radiotherapy Fails to Show Long-Term Survival Benefit in High-Risk Localized Prostate Cancer
@ascocancer.bsky.social #GU26 #pcsm www.onclive.com/view/cabazit...
WATCH: Alan H. Bryce, MD, of @cityofhope.bsky.social, discusses the significance of the FDA’s regular approval of rucaparib for the treatment of BRCA mutation–associated mCRPC previously treated with an AR-directed therapy #pcsm #oncology
www.onclive.com/view/dr-bryc...
Lutetium Lu 177 Vipivotide Tetraxetan Plus ADT and an ARPI Maintains QOL in mHSPC @mskcancercenter.bsky.social @ascocancer.bsky.social #GU26 #pcsm #oncology
www.onclive.com/view/lutetiu...
Capivasertib Added to Abiraterone Extends rPFS in PTEN-Deficient mHSPC @dukecancer.bsky.social @ascocancer.bsky.social #GU26 #pcsm #oncology
www.onclive.com/view/capivas...
Figure of functional change after treatment, between open RP and 2-D RT. https://www.nejm.org/doi/full/10.1056/NEJMoa1209978
#ASCO #GU26
Session on localized #ProstateCancer
Dr. Ron Chen highlights functional impacts, comparing RP v RT
*Emphasizes for PCOS that was much less sophisticated radiation
I would add that was much less sophisticated surgery (open RRP) #pcsm
#ASCO #GU26
Re: comment from the audience:
I appreciate the patient advocate sharing he has a new #prostatecancer diagnosis stemming from his getting a #PSA spurred by the Super Bowl Ad!
#ScreeningSavesLives
www.relaxitsabloodtest.com?site=GK10010...
#pcsm
Phase 2: Cooled focal therapy shows 88% success in #prostatecancer at 12 mo. 🔬
• No urinary incontinence 📊
• 100% potency retention
• High QoL profile
Via @bjuijournal.bsky.social @renalurologynews.bsky.social.
Read more: https://bit.ly/4cB2rF9
#GUsm #MedEd #Oncology #pcsm
WATCH 👀: Mehmet Bilen, MD, of @winshipcancer.emory.edu discusses findings from a real-world analysis of apalutamide vs darolutamide in mCSPC.
See the whole video here 📽️: www.onclive.com/view/dr-bile...
#oncology #pcsm #mcspc
WATCH 👀: Mehmet Bilen, MD, of @winshipcancer.emory.edu discusses a real-world analysis of apalutamide vs darolutamide in mCSPC.
See the whole video here ➡️: www.onclive.com/view/dr-bile...
#oncology #medtwitter #prostatecancer #pcsm #mcspc
Real-World Analysis Establishes OS Advantage With Apalutamide Plus ADT vs Darolutamide in mCSPC @emoryuniversity.bsky.social @winshipcancer.emory.edu #pcsm #oncology
www.onclive.com/view/real-wo...
#ProstateCancer often has a "cold" tumor microenvironment. A novel autovaccine aims to "reawaken" the immune response via patient-specific antigens. 🩺
Via @renalurologynews.bsky.social: • High specificity • Low toxicity
Read: https://bit.ly/4rgohC2
#pcsm #oncology #immunotherapy
#Prostatecancer metastasis risk is increased for men with vs without cribriform morphology, investigators report. Research from Nikita Sushentsev, MD. Article from @renalurologynews.bsky.social.
https://bit.ly/4t7eEXV
#pcsm
Docetaxel rechallenge improved overall survival compared with switching to cabazitaxel, for patients with chemonaïve #mCRPC who did not experience progression during prior treatment with docetaxel. From @jamanetworkopen.com.
Read more here: ➡️ https://bit.ly/3NGNEyj
#prostatecancer #pcsm
The consumption of a number of widely used food #preservatives is linked to an increased risk of overall, breast, and prostate #cancers. Published in @bmj.com.
https://bit.ly/3NmnUHw
#CancerRisk #bcsm #pcsm
#Prostatecancer patients with metastatic disease and low-volume primary tumors appear to have a poor prognosis.
https://bit.ly/49vP8nF
#pcsm #gucsm
The administration of leuprorelin acetate after radical #prostatectomy does not provide survival benefits in patients with nonmetastatic, high-risk #prostatecancer who have undetectable prostate-specific antigen levels. Reported in @eururoloncol.bsky.social.
https://bit.ly/4sHEEJw
#pcsm
Researchers Uncover How a Key Oncogene Drives Prostate Cancer at Its Earliest Stage @foxchasecancer.bsky.social #oncology #pcsm #prostatecancer
www.onclive.com/view/researc...
